NASDAQ:CGON CG Oncology Q4 2024 Earnings Results & Report $74.40 +4.25 (+6.06%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$72.00 -2.40 (-3.23%) As of 11/13/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CG Oncology missed analyst earnings expectations but beat on revenue in its Q4 2024 results, released March 25, 2025. The company reported EPS of -$0.48 versus the -$0.37 consensus estimate, while revenue of $460 thousand topped the $107 thousand estimate by $353.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 25, 2025TimeBefore Market OpensConference Call DateMarch 28, 2025Conference Call7:00 AM ET CG Oncology EPS ResultsActual EPS-$0.48Consensus EPS -$0.37Beat/MissMissed by -$0.11One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCG Oncology Revenue ResultsActual Revenue$460 thousandExpected Revenue$107 thousandBeat/MissBeat by +$353.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) CG Oncology Q4 2024 Earnings FAQ Did CG Oncology beat earnings estimates for Q4 2024? CG Oncology (NASDAQ:CGON) reported earnings of -$0.48 per share for Q4 2024, missing the consensus estimate of -$0.37. The report was announced on Tuesday, March 25, 2025. What was CG Oncology's revenue for Q4 2024? CG Oncology reported revenue of $460 thousand for Q4 2024, against a consensus estimate of $107 thousand. CG Oncology Earnings HeadlinesCG Oncology Rises as Investors Position for Near-Term Trial Data and Aftermath of Q3 BeatNovember 13 at 4:31 PM | quiverquant.comQCG Oncology FY2026 Earnings Forecast Lifted by HC WainwrightNovember 12 at 2:15 AM | americanbankingnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 14 at 1:00 AM | Behind the Markets (Ad)CG Oncology (NASDAQ:CGON) Stock Price Target Cut by GuggenheimNovember 11 at 2:51 AM | americanbankingnews.comWhat CG Oncology (CGON)'s Third Quarter Earnings Means For ShareholdersNovember 10, 2026 | finance.yahoo.comCG Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMSee More CG Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email. Email Address About CG OncologyCG Oncology (NASDAQ:CGON) is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response. CG Oncology has no approved commercial products. Its clinical development program includes studies of cretostimogene alone and in combination with other cancer treatments. The company is led by President and Chief Executive Officer Arthur Kuan.View CG Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
